Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Apr;66(4):677-679.
doi: 10.1016/j.jhep.2016.11.028. Epub 2016 Dec 10.

Advancing hepatitis B virus entry inhibitors

Eloi R Verrier  1 , Catherine Schuster  1 , Thomas F Baumert  2
Affiliations
Editorial

Advancing hepatitis B virus entry inhibitors

Eloi R Verrier et al. J Hepatol. 2017 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

The authors declared that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.

Figures

Fig. 1
Fig. 1. Model of interaction of selected HBV entry inhibitors and Na+-taurocholate cotransporting polypeptide (NCTP) at the hepatocyte basolateral membrane
According to Shimura and colleagues, CSY995, a CsA derivative exhibiting no immunosuppressive activity, contrary to CsA, appears to bind to NTCP via an alternative site (putatively overlapping with the bile acid pocket site of the protein), allowing bile acid transport in spite of a strong anti-HBV activity. Myrcludex B (MyrB) is a myristoylated peptide derived from the HBV envelope specifically binding to NTCP, inhibiting both HBV entry and bile acid transport. CsA, cyclosporine A; HBV, hepatitis B virus.
See this image and copyright information in PMC

Comment on

References

    1. Zeisel MB, Lucifora J, Mason WS, Sureau C, Beck J, Levrero M, et al. Towards an HBV cure: state-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure. Gut. 2015;64:1314–1326. - PubMed
    1. Levrero M, Testoni B, Zoulim F. HBV cure: why, how, when? Curr Opin Virol. 2016;18:135–143. - PubMed
    1. Trepo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014;384:2053–2063. - PubMed
    1. Petersen J, Thompson AJ, Levrero M. Aiming for cure in HBV and HDV infection. J Hepatol. 2016;65:835–848. - PubMed
    1. Urban S, Bartenschlager R, Kubitz R, Zoulim F. Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology. 2014;147:48–64. - PubMed

Substances

LinkOut - more resources